Effect of tolterodine on gastrointestinal transit and bowel habits in healthy subjects

Adil Eddie Bharucha, B. Seide, Z. Guan, C. N. Andrews, A. R. Zinsmeister

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Clinical trials and observations suggest that constipation is an uncommon side effect of treating overactive bladder with the muscarinic receptor antagonist tolterodine. Because muscarinic antagonism inhibits gastrointestinal motor activity, we evaluated the effects of tolterodine on bowel habits, gastrointestinal and colonic transit in healthy subjects. In this double-blind study, 36 healthy subjects were randomized to tolterodine extended release (ER, 4 mg daily) or placebo for 6 days. Gastric emptying (GE), small bowel and colonic transit were assessed on days 4-6 by scintigraphy. Bowel habits were recorded by diaries. Tolterodine did not significantly affect half-time for GE (GE thalf) [116 ± 6 min (mean ± SEM) for placebo vs 126 ± 7 min for tolterodine], small bowel transit measured by colonic filling at 6 h (45 ± 6% for placebo vs 36 ± 6% for tolterodine) or the geometric center of colonic transit at 24 h (2.9 ± 0.2 for placebo vs 2.6 ± 0.3 for tolterodine). Subjects who received tolterodine had slightly fewer bowel movements (i.e. 1.34 ± 0.1 stools per day for placebo vs 1.0 ± 0.1 for tolterodine; P = 0.02 for treatment effect). Tolterodine did not significantly affect stool consistency or ease of defecation. At the therapeutic dose used to treat overactive bladder, tolterodine did not significantly affect gastrointestinal or colonic transit and had minor effects on bowel habits in healthy subjects. Further studies are necessary to elucidate whether these observations are explained by tolterodine effects at muscarinic receptors which stimulate and inhibit gastrointestinal motility.

Original languageEnglish (US)
Pages (from-to)643-648
Number of pages6
JournalNeurogastroenterology and Motility
Volume20
Issue number6
DOIs
StatePublished - Jun 2008

Fingerprint

Gastrointestinal Transit
Habits
Healthy Volunteers
Placebos
Gastric Emptying
Overactive Urinary Bladder
Muscarinic Receptors
Tolterodine Tartrate
Muscarinic Antagonists
Gastrointestinal Motility
Defecation
Constipation
Double-Blind Method
Radionuclide Imaging
Cholinergic Agents

Keywords

  • Antagonist
  • Colonic
  • Gastrointestinal
  • Muscarinic
  • Tolterodine
  • Transit

ASJC Scopus subject areas

  • Physiology
  • Gastroenterology
  • Neuroscience(all)

Cite this

Effect of tolterodine on gastrointestinal transit and bowel habits in healthy subjects. / Bharucha, Adil Eddie; Seide, B.; Guan, Z.; Andrews, C. N.; Zinsmeister, A. R.

In: Neurogastroenterology and Motility, Vol. 20, No. 6, 06.2008, p. 643-648.

Research output: Contribution to journalArticle

Bharucha, Adil Eddie ; Seide, B. ; Guan, Z. ; Andrews, C. N. ; Zinsmeister, A. R. / Effect of tolterodine on gastrointestinal transit and bowel habits in healthy subjects. In: Neurogastroenterology and Motility. 2008 ; Vol. 20, No. 6. pp. 643-648.
@article{2a394fd8435f4cf4a68b6da1534189f6,
title = "Effect of tolterodine on gastrointestinal transit and bowel habits in healthy subjects",
abstract = "Clinical trials and observations suggest that constipation is an uncommon side effect of treating overactive bladder with the muscarinic receptor antagonist tolterodine. Because muscarinic antagonism inhibits gastrointestinal motor activity, we evaluated the effects of tolterodine on bowel habits, gastrointestinal and colonic transit in healthy subjects. In this double-blind study, 36 healthy subjects were randomized to tolterodine extended release (ER, 4 mg daily) or placebo for 6 days. Gastric emptying (GE), small bowel and colonic transit were assessed on days 4-6 by scintigraphy. Bowel habits were recorded by diaries. Tolterodine did not significantly affect half-time for GE (GE thalf) [116 ± 6 min (mean ± SEM) for placebo vs 126 ± 7 min for tolterodine], small bowel transit measured by colonic filling at 6 h (45 ± 6{\%} for placebo vs 36 ± 6{\%} for tolterodine) or the geometric center of colonic transit at 24 h (2.9 ± 0.2 for placebo vs 2.6 ± 0.3 for tolterodine). Subjects who received tolterodine had slightly fewer bowel movements (i.e. 1.34 ± 0.1 stools per day for placebo vs 1.0 ± 0.1 for tolterodine; P = 0.02 for treatment effect). Tolterodine did not significantly affect stool consistency or ease of defecation. At the therapeutic dose used to treat overactive bladder, tolterodine did not significantly affect gastrointestinal or colonic transit and had minor effects on bowel habits in healthy subjects. Further studies are necessary to elucidate whether these observations are explained by tolterodine effects at muscarinic receptors which stimulate and inhibit gastrointestinal motility.",
keywords = "Antagonist, Colonic, Gastrointestinal, Muscarinic, Tolterodine, Transit",
author = "Bharucha, {Adil Eddie} and B. Seide and Z. Guan and Andrews, {C. N.} and Zinsmeister, {A. R.}",
year = "2008",
month = "6",
doi = "10.1111/j.1365-2982.2008.01089.x",
language = "English (US)",
volume = "20",
pages = "643--648",
journal = "Neurogastroenterology and Motility",
issn = "1350-1925",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Effect of tolterodine on gastrointestinal transit and bowel habits in healthy subjects

AU - Bharucha, Adil Eddie

AU - Seide, B.

AU - Guan, Z.

AU - Andrews, C. N.

AU - Zinsmeister, A. R.

PY - 2008/6

Y1 - 2008/6

N2 - Clinical trials and observations suggest that constipation is an uncommon side effect of treating overactive bladder with the muscarinic receptor antagonist tolterodine. Because muscarinic antagonism inhibits gastrointestinal motor activity, we evaluated the effects of tolterodine on bowel habits, gastrointestinal and colonic transit in healthy subjects. In this double-blind study, 36 healthy subjects were randomized to tolterodine extended release (ER, 4 mg daily) or placebo for 6 days. Gastric emptying (GE), small bowel and colonic transit were assessed on days 4-6 by scintigraphy. Bowel habits were recorded by diaries. Tolterodine did not significantly affect half-time for GE (GE thalf) [116 ± 6 min (mean ± SEM) for placebo vs 126 ± 7 min for tolterodine], small bowel transit measured by colonic filling at 6 h (45 ± 6% for placebo vs 36 ± 6% for tolterodine) or the geometric center of colonic transit at 24 h (2.9 ± 0.2 for placebo vs 2.6 ± 0.3 for tolterodine). Subjects who received tolterodine had slightly fewer bowel movements (i.e. 1.34 ± 0.1 stools per day for placebo vs 1.0 ± 0.1 for tolterodine; P = 0.02 for treatment effect). Tolterodine did not significantly affect stool consistency or ease of defecation. At the therapeutic dose used to treat overactive bladder, tolterodine did not significantly affect gastrointestinal or colonic transit and had minor effects on bowel habits in healthy subjects. Further studies are necessary to elucidate whether these observations are explained by tolterodine effects at muscarinic receptors which stimulate and inhibit gastrointestinal motility.

AB - Clinical trials and observations suggest that constipation is an uncommon side effect of treating overactive bladder with the muscarinic receptor antagonist tolterodine. Because muscarinic antagonism inhibits gastrointestinal motor activity, we evaluated the effects of tolterodine on bowel habits, gastrointestinal and colonic transit in healthy subjects. In this double-blind study, 36 healthy subjects were randomized to tolterodine extended release (ER, 4 mg daily) or placebo for 6 days. Gastric emptying (GE), small bowel and colonic transit were assessed on days 4-6 by scintigraphy. Bowel habits were recorded by diaries. Tolterodine did not significantly affect half-time for GE (GE thalf) [116 ± 6 min (mean ± SEM) for placebo vs 126 ± 7 min for tolterodine], small bowel transit measured by colonic filling at 6 h (45 ± 6% for placebo vs 36 ± 6% for tolterodine) or the geometric center of colonic transit at 24 h (2.9 ± 0.2 for placebo vs 2.6 ± 0.3 for tolterodine). Subjects who received tolterodine had slightly fewer bowel movements (i.e. 1.34 ± 0.1 stools per day for placebo vs 1.0 ± 0.1 for tolterodine; P = 0.02 for treatment effect). Tolterodine did not significantly affect stool consistency or ease of defecation. At the therapeutic dose used to treat overactive bladder, tolterodine did not significantly affect gastrointestinal or colonic transit and had minor effects on bowel habits in healthy subjects. Further studies are necessary to elucidate whether these observations are explained by tolterodine effects at muscarinic receptors which stimulate and inhibit gastrointestinal motility.

KW - Antagonist

KW - Colonic

KW - Gastrointestinal

KW - Muscarinic

KW - Tolterodine

KW - Transit

UR - http://www.scopus.com/inward/record.url?scp=43549088527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43549088527&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2982.2008.01089.x

DO - 10.1111/j.1365-2982.2008.01089.x

M3 - Article

C2 - 18312543

AN - SCOPUS:43549088527

VL - 20

SP - 643

EP - 648

JO - Neurogastroenterology and Motility

JF - Neurogastroenterology and Motility

SN - 1350-1925

IS - 6

ER -